Estradiol/progestogen transdermal - Watson

Drug Profile

Estradiol/progestogen transdermal - Watson

Alternative Names: Alnea; Estradiol/progestin transdermal - Watson; Progestin/estradiol transdermal - Watson; Progestogen/estradiol transdermal - Watson; TheraDerm MTX

Latest Information Update: 05 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Watson Pharmaceuticals
  • Class Estradiol congeners; Estrenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 16 Jan 2001 TheraTech is now called Watson Laboratories
  • 23 Nov 2000 The FDA has issued a Non-Approval Letter for his product.
  • 08 Feb 2000 Preregistration for Menopausal syndrome in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top